<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Metronomic chemotherapy has been advocated recently as a novel chemotherapeutic regimen </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="46793">Polyethylene glycol</z:chebi> (<z:chebi fb="77" ids="46793">PEG</z:chebi>)-coated liposomes are well known to accumulate in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> by virtue of the highly permeable angiogenic blood vessels characteristic for growing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue, the so-called "enhanced permeability and retention (EPR) effect" </plain></SENT>
<SENT sid="2" pm="."><plain>To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (l-OHP)-containing <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated liposomes was evaluated in a murine colon <z:mp ids='MP_0002038'>carcinoma</z:mp>-bearing mice model </plain></SENT>
<SENT sid="3" pm="."><plain>S-1 is an oral fluoropyrimidine formulation and metronomic S-1 dosing is a promising alternative to infused 5-FU in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, the combination of S-1 with l-OHP may be an alternative to FOLFOX (infusional 5-FU/leucovorin (LV) in combination with l-OHP), which is a first-line therapeutic regimen of a colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The combination of oral metronomic S-1 dosing with intravenous administration of liposomal l-OHP formulation exerted excellent antitumor activity without severe overlapping side-effects, compared with either metronomic S-1 dosing, free l-OHP or liposomal l-OHP formulation alone or metronomic S-1 dosing plus free l-OHP </plain></SENT>
<SENT sid="6" pm="."><plain>We confirmed that the synergistic antitumor effect is due to prolonged retention of l-OHP in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> on account of the <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated liposomes, presumably via alteration of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment caused by the metronomic S-1 treatment </plain></SENT>
<SENT sid="7" pm="."><plain>The combination regimen proposed here may be a breakthrough in treatment of intractable <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> and an alternative to FOLFOX in advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> therapy with acceptable tolerance and preservation of quality of life (QOL) </plain></SENT>
</text></document>